巨子生物2024上半年营收25.4亿元品牌线上GMV增速超100%

作者：张从容文章来源：亿邦动力

2024-08-21 14:17

作者：张从容文章来源：亿邦动力

2024-08-21 14:17

邦小白快读

全文速览

业绩关键数据

1. 巨子生物2024上半年销售收入25.4亿元，同比增长58.2%，归母净利润9.83亿元，增长47.4%，毛利20.93亿元，增长54.9%，但毛利率从84.1%降至82.4%。

2. 品牌表现突出，可复美收入20.71亿元，增长68.6%，占总收益15.6%；可丽金收入3.96亿元，增长23.6%，占比15.6%。

渠道与产品分布

1. 直销渠道收入18.38亿元，占比72.4%，经销渠道收入7.02亿元，占比27.6%。

2. 产品以功效性护肤品为主，收入19.4亿元，占比76.4%，提升1.9个百分点；医用敷料收入5.92亿元，占比23.3%。

实操动态

1. 线下迅速布局，在西安、重庆、成都等城市购物中心开设约10家店，重庆万象城旗舰店开业。

2. 线上全平台策略，618期间可复美GMV增速超60%，可丽金超100%。

品牌营销成效

1. 可复美品牌收入20.71亿元，同比增长68.6%，占比提升5.1个百分点，显示品牌影响力增强。

2. 可丽金品牌收入3.96亿元，增长23.6%，线上GMV增速超100%，反映营销活动成功。

品牌渠道建设

1. 线下渠道扩展迅速，在公立医院、私立医院及购物中心开设约10家店，重庆旗舰店开业，强化品牌实体存在。

2. 线上全平台布局坚持，618期间GMV高增速体现渠道整合效果，直销占比72.4%主导销售。

消费趋势与产品研发

1. 功效性护肤品收入占比76.4%，提升1.9个百分点，显示消费偏好向功能性产品倾斜。

2. 用户行为观察：线上GMV增速显著，可丽金超100%，表明电商消费需求旺盛，品牌需优化产品线应对趋势。

增长市场与机会

1. 线上消费增长强劲，618期间可复美GMV增速超60%，可丽金超100%，提供高增长销售机会。

2. 线下扩张机会：在西安、重庆、成都等城市开设约10家店，旗舰店开业，显示新市场进入潜力。

风险提示与应对

1. 毛利率下降至82.4%，提示成本控制风险，需优化供应链。

2. 收入集中化风险：功效性护肤品占比76.4%，可复美占比提升，依赖单一品类，需多元化产品。

商业模式与学习点

1. 直销模式成功，收入占比72.4%，可借鉴高效渠道管理。

2. 全平台线上策略，618活动实现GMV高增速，提供事件应对措施范例。

产品生产需求

1. 功效性护肤品是核心产品，收入19.4亿元，占比76.4%，提升1.9个百分点，需求强劲。

2. 医用敷料收入5.92亿元，占比23.3%，保健食品仅860万元，占比0.3%，显示生产重点在护肤品类。

商业机会启示

1. 品牌增长迅速，可复美收入增长68.6%，可丽金增长23.6%，提供代工或合作机会。

2. 数字化推进启示：线上GMV增速超100%（可丽金），显示电商布局重要性，工厂可借力数字化提升效率。

生产优化方向

1. 产品结构集中化，占比提升，提示优化生产线以聚焦高需求品类。

2. 线下渠道扩展，如购物中心开店，启示工厂需支持品牌实体化需求。

行业发展趋势

1. 线上消费加速：618期间可复美GMV增速超60%，可丽金超100%，显示电商持续增长趋势。

2. 线下渠道扩展：在多个城市开设约10家店，旗舰店开业，反映全渠道融合趋势。

客户痛点与解决方案

1. 渠道多元化痛点：直销占比72.4%，经销27.6%，解决方案是全平台线上布局，实现GMV高增长。

2. 增长需求痛点：收入集中依赖功效性护肤品，解决方案是优化产品线，如医用敷料占比23.3%，提供平衡服务。

商业对平台需求

1. 线上GMV高增长需求：618期间可复美增速超60%，可丽金超100%，显示平台需支持品牌活动。

2. 渠道整合需求：直销收入占比72.4%，平台需提供招商机会，吸引品牌入驻。

平台最新做法

1. 招商与运营管理：线下开店约10家，重庆旗舰店开业，平台可借机拓展实体合作。

2. 全平台线上布局坚持，平台需优化运营以维持高增速，如618活动管理。

风险规避

1. 毛利率下降至82.4%，提示平台需监控成本风险，避免利润挤压。

2. 收入集中风险：可复美占比提升，平台需多元化招商以分散依赖。

产业新动向

1. 收入集中化：功效性护肤品占比76.4%，提升1.9个百分点，可复美占比提升5.1个百分点，显示产业向核心产品倾斜。

2. 渠道变化动向：直销渠道占比72.4%主导，线下迅速布局开店，反映线上线下融合趋势。

新问题与启示

1. 毛利率下降至82.4%，未明原因，提示研究成本结构问题，或需政策建议优化。

2. 品牌依赖风险：可复美收入占比高，研究者可分析商业模式可持续性。

商业模式启示

1. 直销模式成功，收入占比高，提供高效渠道管理案例。

2. 全平台策略：线上GMV增速超100%，显示数字商业模式的创新潜力。

声明：快读内容全程由AI生成，请注意甄别信息。如您发现问题，请发送邮件至 run@ebrun.com 。

我是品牌商卖家工厂服务商平台商研究者帮我再读一遍。

Quick Summary

Key Performance Metrics

1. Giant Biogene's H1 2024 revenue reached RMB 25.4 billion, up 58.2% year-on-year. Net profit attributable to owners was RMB 9.83 billion, growing 47.4%, while gross profit hit RMB 20.93 billion, a 54.9% increase. However, the gross margin declined from 84.1% to 82.4%.

2. Brand performance was strong: Curfem revenue grew 68.6% to RMB 20.71 billion, accounting for 81.5% of total revenue; Crowngold revenue increased 23.6% to RMB 3.96 billion, representing 15.6%.

Channel and Product Distribution

1. Direct sales contributed RMB 18.38 billion (72.4% of total), while distributor channels generated RMB 7.02 billion (27.6%).

2. Functional skincare products dominated with RMB 19.4 billion in revenue (76.4%, up 1.9 percentage points), while medical dressings contributed RMB 5.92 billion (23.3%).

Operational Developments

1. Rapid offline expansion: Approximately 10 new stores opened in shopping malls across Xi'an, Chongqing, and Chengdu, including a flagship store in Chongqing MixC.

2. Omnichannel online strategy: During the 618 shopping festival, Curfem's GMV grew over 60%, and Crowngold's exceeded 100%.

Brand Marketing Effectiveness

1. Curfem brand revenue surged 68.6% to RMB 20.71 billion, increasing its share by 5.1 percentage points, demonstrating enhanced brand influence.

2. Crowngold revenue grew 23.6% to RMB 3.96 billion, with online GMV exceeding 100% growth during 618, reflecting successful marketing campaigns.

Brand Channel Development

1. Accelerated offline expansion: Approximately 10 new stores opened across public hospitals, private clinics, and shopping malls, with the Chongqing flagship strengthening physical presence.

2. Sustained omnichannel strategy: High GMV growth during 618 demonstrates integrated channel effectiveness, with direct sales dominating at 72.4% of revenue.

Consumer Trends and Product Development

1. Functional skincare's share rose 1.9 percentage points to 76.4%, indicating consumer preference shift toward efficacy-driven products.

2. User behavior insights: Crowngold's >100% online GMV growth signals robust e-commerce demand, requiring optimized product portfolios to align with trends.

Growth Markets and Opportunities

1. Strong online consumption growth: Curfem's >60% and Crowngold's >100% GMV growth during 618 present high-growth sales opportunities.

2. Offline expansion potential: Approximately 10 new stores in key cities and flagship openings indicate new market entry opportunities.

Risk Alerts and Countermeasures

1. Gross margin decline to 82.4% signals cost control risks, necessitating supply chain optimization.

2. Revenue concentration risk: Functional skincare's 76.4% share and Curfem's growing dominance highlight need for product diversification.

Business Model Insights

1. Successful direct sales model (72.4% revenue share) offers lessons in efficient channel management.

2. Omnichannel online strategy driving high GMV growth during 618 provides exemplary event response tactics.

Production Demand Analysis

1. Functional skincare is core, generating RMB 19.4 billion (76.4%, up 1.9 percentage points), indicating strong demand.

2. Medical dressings contributed RMB 5.92 billion (23.3%), while health foods were minimal at RMB 8.6 million (0.3%), confirming skincare as production focus.

Business Opportunity Insights

1. Rapid brand growth (Curfem +68.6%, Crowngold +23.6%) creates OEM/partnership potential.

2. Digitalization imperative: Crowngold's >100% online GMV growth underscores e-commerce importance, suggesting efficiency gains through digital integration.

Production Optimization Directions

1. Concentrated product structure suggests streamlining production lines for high-demand categories.

2. Offline expansion (e.g., mall stores) indicates need to support brands' physical retail requirements.

Industry Trend Analysis

1. Accelerated online consumption: >60% (Curfem) and >100% (Crowngold) GMV growth during 618 confirms e-commerce momentum.

2. Offline channel expansion: ~10 new stores across multiple cities reflect omnichannel integration trend.

Client Pain Points and Solutions

1. Channel diversification challenge: 72.4% direct sales vs. 27.6% distribution requires omnichannel solutions like integrated online platforms for GMV growth.

2. Growth concentration risk: Overreliance on functional skincare (76.4%) necessitates balanced product portfolios, with medical dressings (23.3%) offering diversification pathways.

Platform Demand Insights

1. High GMV growth needs: >60% (Curfem) and >100% (Crowngold) growth during 618 requires platform support for brand campaigns.

2. Channel integration demand: 72.4% direct sales share indicates need for merchant acquisition strategies to attract brands.

Platform Strategy Implications

1. Merchant management opportunities: Offline expansion (~10 stores, flagship opening) enables physical partnership extensions.

2. Omnichannel optimization requirement: Sustained high GMV growth necessitates enhanced operational support for events like 618.

Risk Mitigation Focus

1. Gross margin decline to 82.4% warrants cost monitoring to prevent profit compression.

2. Revenue concentration risk: Curfem's growing share demands diversified merchant base to reduce dependency.

Industry Dynamics

1. Revenue concentration: Functional skincare's 76.4% share (+1.9ppt) and Curfem's expanding dominance (+5.1ppt) indicate industry tilt toward core products.

2. Channel evolution: Direct sales' 72.4% dominance and rapid offline store openings reflect omnichannel integration trend.

Emerging Issues and Implications

1. Gross margin decline to 82.4% warrants cost structure analysis, potentially informing policy optimization recommendations.

2. Brand dependency risk: Curfem's high revenue share invites scrutiny of business model sustainability.

Business Model Insights

1. Successful direct sales model (high revenue share) offers case study in efficient channel management.

2. Omnichannel strategy innovation: >100% online GMV growth demonstrates digital business model potential.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】日前，巨子生物发布2024年中期业绩报告。截至2024年6月20日，巨子生物控股有限公司销售收入同比增长58.2%至25.4亿元，归母净利润同比增长47.4%至9.83亿元，毛利同比增长54.9%至20.93亿元，毛利率由去年同期的84.1%下降至82.4%。

其中，巨子生物旗下品牌可复美收入达20.71亿元，同比增长68.6%，占总收益的15.6%，可丽金品牌收入达3.96亿元，同比增长23.6%，占比15.6%；直销渠道收入18.38亿元，占比72.4%，经销渠道收入7.02亿元，占比27.6%。

巨子生物的收入来源仍以功效性护肤品为主。2024年上半年，巨子生物功效性护肤品收入19.4亿元，占比76.4%，医用敷料收入5.92亿元，占比23.3%，保健食品及其他收入860万元，占比0.3%。

相比于去年，今年巨子生物各领域和品牌产品收入更加集中，如功效性护肤品占比提升1.9个百分点，可复美品牌收入占比提升5.1个百分点。

今年上半年，巨子生物迅速布局线下，除公立医院、私立医院、诊所等专业渠道外，旗下品牌可复美在西安、重庆、程度等城市购物中心开设约10家线下店。今年6月16日，可复美全国首家品牌旗舰店于重庆万象城正式开业。同时，在线上，巨子生物坚持全平台布局，今年618期间，可复美和可丽金在线上的GMV增速分别超过60%和100%。

亿邦持续追踪报道，如想了解更多与本文相关信息，请扫码关注作者微信。

【版权提示】亿邦动力倡导尊重与保护知识产权。未经许可，任何人不得复制、转载、或以其他方式使用本网站的内容。如发现本站文章存在版权问题，烦请提供版权疑问、身份证明、版权证明、联系方式等发邮件至run@ebrun.com，我们将及时沟通与处理。

已点赞

好文章,值得被更多人看到

FAQ回顾

巨子生物2024年上半年主要财务数据是什么？

巨子生物2024年上半年销售收入25.4亿元，同比增长58.2%；归母净利润9.83亿元，同比增长47.4%；毛利率为82.4%。

巨子生物旗下可复美和可丽金品牌表现如何？

可复美品牌收入20.71亿元，同比增长68.6%，占总收益15.6%；可丽金品牌收入3.96亿元，同比增长23.6%，占比15.6%。

巨子生物线上销售渠道有何增长？

2024年618期间，可复美和可丽金在线上GMV增速分别超过60%和100%。直销渠道收入占比72.4%，为主要销售模式。

标签:: 化妆品国货巨子生物未来零售

是时候重新认识海康威视了

在安防领域持续引领的同时，海康威视另一只脚已经迈进“场景数字化”的赛道。

案例研究未来零售

2024-08-21 13:46:54